Skip to main content
65°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vera Therapeutics Inc Cl A
(NQ:
VERA
)
39.30
+0.18 (+0.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vera Therapeutics Inc Cl A
< Previous
1
2
3
4
5
6
7
Next >
(VERA) - Analyzing Vera Therapeutics's Short Interest
January 31, 2024
Via
Benzinga
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
January 29, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
January 29, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
January 26, 2024
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.
Via
Benzinga
Recap: Vera Therapeutics Q3 Earnings
November 09, 2023
Via
Benzinga
What's Going On With Vera Therapeutics Stock Today?
January 26, 2024
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.
Via
Benzinga
Exposures
Product Safety
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 26, 2024
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 26, 2024
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
January 26, 2024
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.
Via
Benzinga
Topics
Government
Exposures
Political
Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday
January 26, 2024
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings
January 25, 2024
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 25, 2024
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via
Benzinga
Why Is Immunology Disease Focused Vera Therapeutics Stock Trading Higher Today?
January 25, 2024
Vera Therapeutics' 72-week data from Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR.
Via
Benzinga
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
January 25, 2024
U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
January 25, 2024
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
January 25, 2024
Via
Benzinga
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
January 25, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Why Vera Therapeutics Stock Soared by 22% This Week
January 12, 2024
Executive changes and a bullish analyst take combined to boost sentiment on the company.
Via
The Motley Fool
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
January 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
January 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...
Via
Benzinga
Exposures
Product Safety
Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst
December 18, 2023
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion...
Via
Benzinga
This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street
December 15, 2023
Is the stock's risk worth the potential reward?
Via
The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 20, 2023
Via
Benzinga
Synaptics To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday
November 10, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 09, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
November 04, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics Scheduled to Present at November Investor Conferences
October 30, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
October 13, 2023
From
Vera Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.